Apogee Therapeutics, Inc.
Ownership
Ownership Structure
Who owns Apogee Therapeutics, Inc. (APGE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 94.0% of the shares are freely tradable; institutional investors hold 131.6%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Investment Management,Inc. | 13.62 | 10,300,984 | +140.2 | 03/31/2026 |
| FMR Inc | 12.25 | 9,262,291 | +12.6 | 03/31/2026 |
| VR Adviser, LLC | 11.23 | 8,493,321 | +0.0 | 03/31/2026 |
| BlackRock Inc | 5.40 | 4,085,651 | +8.0 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 3.68 | 2,782,097 | +2.6 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.31 | 2,502,095 | +0.0 | 03/31/2026 |
| HHG PLC | 3.12 | 2,360,596 | +14.4 | 03/31/2026 |
| State Street Corp | 2.86 | 2,162,964 | +28.0 | 03/31/2026 |
| Driehaus Capital Management LLC | 2.54 | 1,920,800 | -12.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.48 | 1,876,864 | +0.3 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | McKenna Mark C. | Director | Other | 20,000 | – | – |
| Sep 3, 2026 | Jones William A Jr | Director | Other | 34,824 | – | – |
| Sep 3, 2026 | Dambkowski Carl | Chief Medical Officer | Other | 167,123 | – | – |
| Sep 3, 2026 | Fox Jennifer A. | Director | Other | 34,824 | – | – |
| Sep 3, 2026 | Henderson Jane | Chief Financial Officer | Other | 158,371 | – | – |
| Sep 3, 2026 | Henderson Michael Thomas | Chief Executive Officer | Other | 920,941 | – | – |
| Sep 3, 2026 | Shah Nimish P | Director | Other | 1,750,000 | 135.11 | 236,442,500 |
| Sep 3, 2026 | Fairmount Funds Management LLC | Director | Other | 51,166 | – | – |
| Sep 3, 2026 | Fairmount Funds Management LLC | Director | Other | 340,855 | – | – |
| Sep 2, 2026 | Dambkowski Carl | Chief Medical Officer | Other | 1,375 | 135.06 | 185,708 |
| Aug 7, 2026 | Fairmount Funds Management LLC | Director | Other | 10,370 | 43.85 | 454,725 |
| Aug 7, 2026 | Fairmount Funds Management LLC | Director | Other | 31,838 | 17.00 | 541,246 |
| Aug 5, 2026 | Dambkowski Carl | Chief Medical Officer | Sell | 5,500 | 134.17 | 737,935 |
| Aug 5, 2026 | Dambkowski Carl | Chief Medical Officer | Other | 4,125 | 22.86 | 94,298 |
| Jul 24, 2026 | Henderson Jane | Chief Financial Officer | Other | 15,000 | 0.00 | – |
| Jul 14, 2026 | Dambkowski Carl | Chief Medical Officer | Other | 8,000 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.